Cytogenetic and molecular genetic aspects of eosinophilic leukaemias.
Bain
Barbara J
BJ
Department of Haematology, St Mary's Hospital Campus, Imperial College Faculty of Medicine, St Mary's Hospital, London, UK. b.bain@imperial.ac.uk
D001549:Benzamides; D020732:Cytogenetic Analysis; D003937:Diagnosis, Differential; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004804:Eosinophils / Q000502:physiology*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000235:genetics* / Q000628:therapy; D000068877:Imatinib Mesylate; D009154:Mutation; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D051496:Receptor, Fibroblast Growth Factor, Type 1; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000235:genetics; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics; D014178:Translocation, Genetic
D001549:Benzamides; D004791:Enzyme Inhibitors; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D017468:Receptors, Fibroblast Growth Factor; D000068877:Imatinib Mesylate; C496348:FGFR1 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051496:Receptor, Fibroblast Growth Factor, Type 1; D020797:Receptor, Platelet-Derived Growth Factor beta